Tissue-retentive cpg formulation for enhanced tumor immunotherapy
Kinimmune's tissue-retentive CpG formulation offers localized immunostimulation for solid tumors, enhancing therapy efficacy while reducing systemic side effects. This innovative approach aims to transform 'cold' tumors into 'hot' ones, improving outcomes with current immunotherapies.
Overview
Kinimmune has developed a novel tissue-retentive CpG formulation designed to enhance immunotherapy for solid tumors. By converting CpG immunostimulants into cationic nanocomplexes, this formulation ensures prolonged retention in the tumor microenvironment. This method aims to recruit and activate immune cells effectively, turning 'cold' tumors 'hot' and synergizing with standard immunotherapies like checkpoint inhibitors. The formulation minimizes systemic exposure, thereby reducing immune-related adverse events and broadening the therapeutic window.
Technical specifications
- Localized retention: The cationic nanocomplexes format retains CpG in tumor tissues for extended periods, enhancing local immunostimulation.
- Reduced systemic exposure: Up to 1000X lower systemic immune-related adverse event markers, such as IL-6, compared to naked CpG.
- Enhanced uptake and efficacy: Improved innate immune cell uptake and reduced dosing frequency, leading to significant reductions in tumor growth.
- Abscopal effect evaluation: Future studies will assess the treatment's ability to influence untreated tumors, demonstrating systemic immune activation despite localized application.
Technology readiness level
The technology is currently at TRL 5, with pilot studies demonstrating promising results in tumor growth reduction and immune cell activation. The next phase involves further validation in preclinical models, focusing on poorly immunogenic tumors to confirm efficacy and safety.
About Kinimmune, Inc.
Kinimmune is a clinical-stage biopharmaceutical company that develops intratumoral immunostimulants designed to enhance the efficacy of cancer treatments, particularly checkpoint inhibitors, in solid tumors. The company utilizes proprietary tissue-retentive formulations to keep therapeutic compounds at the site of injection, which allows for potent localized immune activation while minimizing systemic exposure and associated off-target adverse effects. Their technology aims to turn immune-cold tumors into hot environments, potentially expanding the range of patients who can benefit from immunotherapy.
Founded in 2020 and headquartered in St. Louis, the company originated from research at the University of Kansas and Washington University in St. Louis. Their pipeline includes KIN-101, which is in clinical development, along with preclinical and discovery-stage programs like KIN-102. Kinimmune has received non-dilutive funding, including awards from the National Cancer Institute, to support the advancement of these candidates. By leveraging pharmaceutical components with established safety profiles, the company seeks to create quick-to-market interventions that address unmet medical needs for patients with solid tumors.
delivered to your inbox.